ArticleExperimental & molecular medicine2021
Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis.
Article in Experimental & molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 125 citations in OpenAlex.
- Unraveling the Mechanistic Insights ofNutrients · 2026Review
- Article
- Exosomes in depression: mechanistic insights, diagnostic potential, and therapeutic opportunities.Molecular psychiatry · 2026Review
- Comparative Proteomic Analysis of the Striatum in Heterozygous and Null DAT Knockout Rats.International journal of molecular sciences · 2026Article
- Opposing Changes in Cerebellar Dopaminergic Genes Co-Expression Networks in Different Models of Neurodevelopmental Disorders.International journal of molecular sciences · 2026Article
- Dopamine-Derived Oxidative Stress in Attention-Deficit/Hyperactivity Disorder: A Narrative Review of Molecular Mechanisms, Neural Circuitry, and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Mitochondria-Targeted Quinoline-Based Fluorescent Probes for Imaging of Viscosity and MAO‑A with High-Throughput Inhibitor Screening.Chemical & biomedical imaging · 2026Article
- Disruption of Dopamine Homeostasis by Psychostimulants.Molecular neurobiology · 2026Review
- Sex and Diet Biased Effect of L-DOPA on Iron Accumulation in the Ventral Midbrain.Journal of neurochemistry · 2026Article
- Article
- Retrospective Study of the Physiological and Molecular Features of the S-FUS (1-359) Mouse Transgenic Model with an ALS-like Phenotype: Lifespan, Body Weight Dynamics, Movement Disorders, and Dysregulation of the Dopaminergic System.Journal of molecular neuroscience : MN · 2026Article
- Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach.Frontiers in pharmacology · 2026Review
- Gestational physical exercise prevents early-life behavioral impairments in the offspring of a rat model of attention deficit hyperactivity disorder.Scientific reports · 2025Article
- Polyphenol-Enriched Extracts from Leaves of Mediterranean Plants as Natural Inhibitors of Monoamine Oxidase (MAO)-A and MAO-B Enzymes.Nutrients · 2025Article
- Neurotoxicity and Potential Mechanisms of Exposure to Per- and Polyfluoroalkyl Substances (PFASs).Molecular neurobiology · 2025Review
- The neuromodulatory effects ofFood science and biotechnology · 2025Article
- A Comprehensive Approach to the Antidepressant-like Effect and Toxicity ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease.Molecular neurobiology · 2025Review
- Systematic Analysis of SH-SY5Y Differentiation Protocols and Neuronal Subtype Abundance.Cellular and molecular neurobiology · 2025Article
- Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update.Pharmaceuticals (Basel, Switzerland) · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoamine oxidase (MAO) is believed to mediate the degradation of monoamine neurotransmitters, including dopamine, in the brain. Between the two types of MAO, MAO-B has been believed to be involved in dopamine degradation, which supports the idea that the therapeutic efficacy of MAO-B inhibitors in Parkinson's disease can be attributed to an increase in extracellular dopamine concentration. However, this belief has been controversial. Here, by utilizing in vivo phasic and basal electrochemical monitoring of extracellular dopamine with fast-scan cyclic voltammetry and multiple-cyclic square wave voltammetry and ex vivo fluorescence imaging of dopamine with GRAB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.